Clinical Trial Update: A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing different doses of NN0519-0130 for lowering blood sugar in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NN0519-0130 (NN0519-0130)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED